PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 13849734

Newer hormonal preparations.

R F ESCAMILLA
View original source ↗Export metadata ↓

Abstract

A review of the present status of various hormonal substances is presented. The pituitary preparations include various growth hormones (human and beef), still used only experimentally, thyrotropic hormone, used mainly for testing thyroid function, corticotropin-widely used-and gonadotropic hormone.Thyroid, thyroxin and triiodothyronine preparations are considered, with USP thyroid still being most useful. Glucagon may be of some use in terminating hypoglycemia - tolbutamide is now used in many older diabetic persons. New adrenal cortical steroids are still appearing and show variation in effects; cortisone or hydrocortisone remain relatively inexpensive. Many combinations are available. The newest addition to available male hormone preparations is fluoxymesterone which is anabolic in smaller dosage than the older forms. Several new long acting preparations of androgens, estrogens and progesterone are available, and many ingenious combinations are presented.

Explore related subjects

Adrenal Cortex HormonesAdrenocorticotropic HormoneAndrogensCortisoneGrowth HormoneHormonesHumansHydrocortisoneHypoglycemiaMalePituitary GlandProgesteroneThyrotropinThyroxineTriiodothyronineHORMONESJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R F ESCAMILLA. 1960. Newer hormonal preparations.. https://pubmed.ncbi.nlm.nih.gov/13849734/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗
PubMed2007

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗